Clarkston Capital Partners LLC Acquires 500 Shares of Stryker Corporation $SYK

Clarkston Capital Partners LLC boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 14.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,072 shares of the medical technology company’s stock after purchasing an additional 500 shares during the quarter. Clarkston Capital Partners LLC’s holdings in Stryker were worth $1,611,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Consolidated Portfolio Review Corp lifted its holdings in shares of Stryker by 4.2% in the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock worth $256,000 after buying an additional 26 shares in the last quarter. Princeton Global Asset Management LLC increased its holdings in Stryker by 16.9% in the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after acquiring an additional 26 shares during the last quarter. Sunflower Bank N.A. lifted its stake in Stryker by 4.0% in the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock worth $275,000 after purchasing an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC boosted its holdings in shares of Stryker by 3.2% during the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after purchasing an additional 27 shares during the last quarter. Finally, Sachetta LLC grew its position in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Down 0.8%

SYK stock opened at $372.04 on Friday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market capitalization of $142.28 billion, a price-to-earnings ratio of 49.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm’s fifty day simple moving average is $369.01 and its two-hundred day simple moving average is $380.43.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $410.00 target price on shares of Stryker in a research report on Friday, November 14th. Evercore ISI reduced their price objective on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Wells Fargo & Company increased their target price on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $448.00 target price on shares of Stryker in a report on Friday, November 14th. Finally, Redburn Partners set a $420.00 price target on shares of Stryker in a research note on Thursday, September 18th. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $434.37.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 522,118 shares of company stock worth $185,381,932 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.